Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Theratechnologies

< Previous 1 2 3 Next >
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Update on its Preclinical Oncology Research Program
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Appoints Jordan Zwick to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Operational Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.